Back to top

Analyst Blog

The pipeline continues to progress well at Dynavax Technologies Corporation (DVAX - Snapshot Report) after it suffered a setback in Jun 2013.

We remind investors that Dynavax suffered a setback in Jun 2013 when the U.S. Food and Drug Administration (FDA) asked for additional safety data in response to a meeting with the agency to discuss the complete response letter (CRL) received earlier in 2013 on its hepatitis B vaccine candidate, Heplisav.

Nevertheless, last month, Dynavax announced that immunogenicity and safety data from two phase III trials (HBV-16 and HBV-17) on Heplisav were published in the journal VACCINE. The data from both the trials were encouraging.

Meanwhile, Dynavax is working on developing other candidates in its pipeline. Dynavax recently initiated dosing for the first trial on candidate AZD1419 in a phase I study.

We note that Dynavax is developing AZD1419, a toll-like receptor (TLR) agonist, for the treatment of asthma in partnership with AstraZeneca (AZN - Analyst Report).

The study will initially assess the safety of AZD1419 as compared to placebo on healthy subjects in single and multiple ascending doses.

Thereafter, the second part of the study will enrol 24 patients suffering from mild asthma. Dynavax expects safety data from the first study of the trial by mid-2014.

Apart from lead candidate Heplisav and AZD1419, Dynavax is developing DV1179 (autoimmune and inflammatory diseases) with GlaxoSmithKline (GSK - Analyst Report).

We note that Dynavax currently does not have any approved product in its portfolio. Hence, we expect investor focus to remain on further pipeline updates.

Dynavax carries a Zacks Rank #4 (Sell). Right now, Actelion Ltd. (ALIOF) looks attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%